¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"trial and error"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • nonsampling error
    ºñÇ¥º»¿ÀÂ÷
  • random error
    ¹«ÀÛÀ§¿ÀÂ÷
  • refractive error
    ±¼ÀýÀÌ»ó
  • standard error
    Ç¥ÁØ¿ÀÂ÷
  • statistical error
    Åë°è¿ÀÂ÷
  • systematic error
    °èÅë¿ÀÂ÷
  • sampling error
    Ç¥º»ÃßÃâ¿ÀÂ÷
  • anxious and fearful personality
    ºÒ¾È°øÆ÷ÀΰÝ
  • arch and band appliance
    Ȱ¶ìÀåÄ¡
  • bilateral cleft lip and palate
    ¾çÂÊÀÔ¼úÀÔõÀå°¥¸²Áõ, ¾çÃø±¸¼ø±¸°³¿­
  • bread-and-butter pericarditis
    »§¹öÅ͸ð¾ç½ÉÀ帷¿°
  • complementary and alternative medicine
    º¸Ãæ´ë¾ÈÀÇÇÐ, º¸¿Ï´ëüÀÇÇÐ
  • Center for Disease Control and Prevention
    Áúº´°ü¸®¿¹¹æ¼¾ÅÍ
  • dilatation and curettage
    Àڱñܾ(¼ú), ÀÚ±Ã¼ÒÆÄ(¼ú)
  • foot-and-mouth disease
    ÀԹߺ´, ±¸Á¦¿ª
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cumulative error
    ´©Àû¿ÀÂ÷
  • error distribution
    ¿ÀÂ÷ºÐÆ÷
  • error
    ÀÌ»ó, ¿ÀÂ÷
  • error theory
    Âø¿ÀÀÌ·Ð
  • inborn error
    ¼±ÃµÀÌ»ó
  • instrumental error
    ±â±â¿ÀÂ÷
  • metabolic error
    ´ë»çÀÌ»ó
  • nonsampling error
    ºñÇ¥º»¿ÀÂ÷
  • random error
    ¹«ÀÛÀ§¿ÀÂ÷
  • refractive error
    ±¼ÀýÀÌ»ó
  • reproduction error
    »ý½ÄÀÌ»ó
  • resonance error
    °ø¸íºÎÁ·µµ
  • sampling error
    Ç¥º»¿ÀÂ÷
  • standard error
    Ç¥ÁØ¿ÀÂ÷
  • statistical error
    Åë°è¿ÀÂ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • General anesthesia, reticular activating system and.
    Àü½Å¸¶Ãë(îïãóئö­), ¸Á»óüȰ¼ºÈ­°è(ØÑßÒô÷üÀàõûùͧ)
  • Gravity, cardiac output and
    Áß·Â(ñìÕô), ½É¹ÚÃâ·®(ãýÚÑõóÕá)
  • KUB= kidney, ureter and bladder
    ½Å-´¢°ü-¹æ±¤ ´Ü¼øÃÔ¿µ
  • Kell antigen and antibody
    ÄÌÇ׿øÇ×ü
  • PACS (picture archiving and communicating system)
    ÆÑ½º, ¿µ»ó ÀúÀå ¹× Àü¼Û ü°è
  • PANSS=Positive and Negative Syndrome Scale
    ¾ç¼º À½¼º ÁõÈıº ôµµ
  • SADS, Schedule for Affective Disorders and Schizophrenia
    Á¤µ¿Àå¾Ö¿Í Á¤½ÅºÐ¿­º´ÀÇ Áø´ÜÀ» À§ÇÑ ¸ñ·Ï
  • SOFAS, Social and Occupational Functioning Assessment Scale
    »çȸ-Á÷¾÷±â´ÉÆò°¡Ã´µµ
  • SONAR(Sound Navigation and Ranging)
    ¼Ò³ª
  • acute and late normal tissue effects
    Á¤»óÁ¶Á÷ ±Þ¼º¿µÇâ, Á¤»óÁ¶Á÷ ¸¸¼º ¿µÇâ
  • alternate hot and cold caloric examination
    ³Ã¿Â±³´ë(¿Âµµ)Àڱذ˻ç(ÕÒè®Îßû»è®öôô§Ð½ËþÞÛ).
  • ambient temperature and pressure saturated with water vapor =ATP
    ½Ç¿Â´ë±â¾Ð ¼öÁõ±â Æ÷È­»óÅÂ
  • american society of therapeutic radiology and onco
    logy (ASTRO) ¹Ì±¹¹æ»ç¼±Á¾¾çÇÐȸ
  • aphthous fever =foot and mouth disease
    ¾ÆÇÁŸ¼º¿­(¡­æð).
  • glioma of optic nerve and chiasm
    ½Ã½Å°æ±³Â÷ ±³¼¼Æ÷Á¾.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • clerical error
    »ç¹«Âø¿À
  • constant error
    Á¤¿ÀÂ÷(ËøËí̤).
  • cumulative error
    ´©Àû¿ÀÂ÷(ÊÙËí̤).
  • curve of error
    ¿ÀÂ÷°î¼±(Ëí̤˭ËÛ).
  • error
    ¿À·ù
  • error
    ÀÌ»ó
  • error distribution
    ¿ÀÂ÷ºÐÆ÷(ÊÙËÓ̰).
  • error of mean square
    Æò±ÕÁ¦°ö¿ÀÂ÷.
  • error of metabolism
    ´ë»ç(ÓÛÞó)ÀÌ»ó.
  • error theory
    Âø¿ÀÀÌ·Ð(ó¹è¦ìµÖå)
  • inborn error
    ¼±Ãµ¼º ÀÌ»ó(¡­ì¶ßÈ).
  • inborn error of metabolism
    ¼±Ãµ¼º ´ë»çÀÌ»ó(Áõ)(¡­ÓÛÞóì¶ßÈñø).
  • inborn error of metabolism
    ¼±Ãµ¼º´ë»çÀÌ»ó(à»ô¸àõÓÛÞóì¶ßÈ)
  • limit of error
    ¿ÀÂ÷ÇѰè(Ëí̤̰˭).
  • mean error
    Æò±Õ¿ÀÂ÷(̰˻Ëí̤).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Mesenteries and peritoneal folds
    âÀÚ°£¸· ¹× º¹¸·ÁÖ¸§
    [¿¾ ¿ë¾î] Àå°£¸·
  • Coeloms and septa
    ü°­°ú Áß°Ý
    [¿¾ ¿ë¾î] ü°­°ú Áß°Ý
  • Gray matter (Nuclei and Columns)
    ȸ»öÁú(½Å°æÇÙ°ú ½Å°æ±âµÕ)
    [¿¾ ¿ë¾î] ȸ¹éÁú
  • Cartilages and Articulations of Larynx
    Èĵο¬°ñ ¹× ÈĵΰüÀý
    [¿¾ ¿ë¾î] Èĵο¬°ñ ¹× ÈĵΰüÀý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • copy error
    º¹»ç ¿À·ù(ÜÜÞÐè¦×½)
  • copy-error mutation
    º¹»ç¿À·ù º¯ÀÌ(ÜÜÞÐè¦×½Ü¨ì¶)
  • error catastrophe
    ¿À·ù Àç³­ (è¦×½î¬Ññ)
  • error curve
    ¿ÀÂ÷ °î¼± (è¦ó¬ÍØàÊ)
  • error function
    ¿ÀÂ÷ ÇÔ¼ö (è¦ó¬ùÞâ¦)
  • error of the first kind
    Á¦ 1 Á¾ ¿ÀÂ÷(è¦ó¬)
  • error of the second kind
    Á¦ 2 Á¾ ¿ÀÂ÷(è¦ó¬)
  • error-prone repair
    ¿À·ùºó¹ß ¼öº¹ (è¦×½ÞºÛ¡áóÜÖ)
  • error theory
    ¿À·ù ÀÌ·Ð (è¦×½×âÖå)
  • Gaussian error curve
    °¡¿ì½º ¿ÀÂ÷ °î¼±(è¦ó¬ ÍØàÊ)
  • inborn error of metabolism
    ¼±Ãµ¼º ´ë»çÀÌ»ó(à»ô¸àõÓÛÞóì¶ßÈ)
  • percentage error
    "ÆÛ¼¾Æ®(¹éºÐÀ²,ÛÝÝÂ×Ë) ¿ÀÂ÷(è¦ó¬)"
  • probable error
    È®·ü ¿ÀÂ÷(ü¬×Ëè¦ó¬)
  • protein error
    ´Ü¹éÁú ¿ÀÂ÷(Ó±ÛÜòõè¦ó¬)
  • random error
    ¿ì¿¬ ¿ÀÂ÷(éÏæÔè¦ó¬)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • salt and pepper appearance
    ¼Ò±ÝÈÄÃß°¡·ç¸ð¾ç
  • SONAR [=Sound Navigation and Ranging]
    ¼Ò³ª
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TE echo-time; expiratory time; tennis elbow; test ear; tetanus; tetracycline; threshold energy; thrombo...
RCT radiotherapy and chemotherapy; randomized clinical trial; randomized controlled trial; registered ca...
ABC absolute basophil count; absolute bone conduction; acalculous biliary colic; acid balance control; a...
ALE active life expectancy; allowable limits of error; amputated lower extremity
'Greek letter alpha' angular acceleration; first [carbon atom next to the carbon atom bearing the active group in organic...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SEM 1-standard error of measurement
CE Constant error
ERN Error-related negativity
MSE Mean Square Error
ME Mean prediction error
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute and late normal tissue effects£¨Á¤»ó Á¶Á÷ ±Þ¼º ¿µÇ⣩

    acute angle

    ¿¹°¢
    Á÷°¢º¸´Ù ÀÛÀº °¢.
  • American Society of Therapeutic Radiology and Oncology
    ¹Ì±¹ ¹æ»ç¼±Á¾¾çÇÐȸ
  • atmospheric temperature and pressure
    ´ë±â Ç¥ÁØ »óÅÂ
  • atrophoderma of Pasini and Pierini
    ÆÄ½Ã´Ï ÇÇ¿¡¸®´Ï ÇǺΠÀ§ÃàÁõ
  • bone and joint surgery
    °ñ°üÀý ¿Ü°ú
  • bread and butter pericarditis
    »§-¹öÅÍ ¸ð¾ç ½É¸·¿°
  • Center for Device and Radiological Health
    ?
  • cheek and tongue retractor
    Çù¼³ °ßÀαâ
  • child abuse and neglect
    ¾Æµ¿ Çдë¿Í ¹æÄ¡
  • communication codes and characteristics
    È­ÀÇ ºÎÈ£¿Í ¼ºÁú
  • congenital and developmental bone disorder
    ¼±Ãµ¼º ¹× ¹ßÀ°¼º °ñ Àå¾Ö
  • congenital and developmental muscle disorder
    ¼±Ãµ¼º ¹× ¹ßÀ°¼º ±ÙÀå¾Ö
    Ãâ»ý ½ÃºÎÅÍ ±ÙÀúÇϸ¦ ³ªÅ¸³»°í Èå´ÃÈå´ÃÇÑ ¾ÆÀÌ. flo
  • connective tissue sheath of Key and Retzius
    Ű-·¹Ä¡¿ì½ºÀÇ °áÇÕ Á¶Á÷ ÃÊ
    ½Å°æ³»¸·, ƯÈ÷ ½Å°æ¼¶À¯ Á¾¸»Áö ÁÖÀ§ÀÇ ¾ãÀº ¿¬Àå.
  • crown and loop space maintainer
    Å©¶ó¿î¿£µå ·çÇÁÇü °£°Ý À¯Áö ÀåÄ¡
  • cultural and ethnic factor
    ¹®È­ ¹ÎÁ·Àû ¿äÀÎ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
type i error The statistical error (said to be of the first kind or alpha error) made in testing an hypothesis when it is concluded that a treatment or intervention is effective when it really is not. Sometimes referred to as a false positive.
(12 Dec 1998)
type II error The statistical error (said to be of the second kind or beta error) made in testing an hypothesis when it is concluded that a treatment or intervention is not effective when it really is. Sometimes referred to as a false negative.
(12 Dec 1998)
experimental error The total error of measurement ascribed to the conduct of an empirical observation. It is commonly expressed as the standard deviation of replicated experiments. There may be many components, including those in the sampling procedure, the measurements, injudicious choice of a model, observer bias, etc.
(05 Mar 2000)
Bernoulli trial A single random event for which there are two and only two possible outcomes that are mutually exclusive and have a priori fixed (and complementary) probabilities of resulting. The trial is the realization of this process. Conventionally one outcome is termed a success and is assigned the score 1, the other is a failure and has the score zero. Thus the outcome might be 0 (no heads, one tail) or 1 (1 head, no tails).
(05 Mar 2000)
randomised controlled trial A clinical trial that involves at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Treatment allocations using coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes, are not truly randomised and a trial employing any of these techniques for patient assignment is designated simply a controlled clinical trial.
(12 Dec 1998)
randomised trial <statistics> A clinical trial in which patients have been randomly assigned to receive either the study drug or alternative treatment, in which neither the patient nor the physician conducting the study know which treatment is being given the patient, and in which the alternative to the study drug is a placebo, the study is conducted at several centres.
(09 Oct 1997)
phase I clinical trial <pharmacology> The earliest stage clinical trial for studying an experimental drug in humans. Phase I trials are generally comparatively small and are used to determine toxicity and maximum dose.
They provide an initial evaluation of a drug's safety and pharmacokinetics-how the drug is absorbed, what tissues it reaches and how long it takes to leave the body. Such studies also usually test various doses of the drug (dose-ranging) to obtain an indication of the appropriate dose to use in later studies.
The patients in these trials usually have advanced disease and have already received best available chemotherapy, therefore, seeing a repose is significant partially because this means there is a lack of cross-resistance between two anti-cancer drugs.
(31 Dec 1997)
phase II clinical trial <pharmacology> Usually focus on the activity of the new product as a single agent in a noncomparative, open study.
(31 Dec 1997)
phase III clinical trial <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments.
Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials.
(31 Dec 1997)
clinical trial <pharmacology> Research study conducted with patients, usually to evaluate a new treatment or drug. Each trial is designed to answer scientific questions and to find better ways to treat individuals with a specific disease.
(12 May 1997)
clinical trial, phase I A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on a small number of healthy persons and conducted over the period of about a year in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase II A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on several hundred volunteers, including a limited number of patients, and conducted over a period of about two years in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase III A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques after phase II trials. A large enough group of patients is studied and closely monitored by physicians for adverse response to long-term exposure, over a period of about three years in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale after clinical trials, phases I, II, and III. These studies, conducted in the united states or a foreign country, often garner additional data about the safety and efficacy of a product.
(12 Dec 1998)
controlled clinical trial A clinical trial involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicine, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trial is characterised as a randomised controlled trial. However, trials employing treatment allocation methods such as coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes are simply designated as controlled clinical trials.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • parity error
    ÆÐ¸®Æ¼ ¿À·ù !
  • personal error
    °³ÀÎÀû ¿ÀÂ÷ 
  • printer's error
    (½ÄÀÚ°ø¿¡ ÀÇÇÑ)¿À½Ä
  • probable error
    È®·ü ¿ÀÂ÷
  • residual error
    ¼³¸íµÇÁö ¾ÊÀº ¿ÀÂ÷ ]
  • again and again
    ¹Ýº¹Çؼ­
  • and
    ±×¸®°í
  • and not ~ either
    ¶Ç ~ ¾Æ´Ï´Ù(=nor)
  • and so forth
    ±âŸ µîµî
  • and so on
    ..µîµî
  • and such
    µûÀ§,µîµî
  • and that
    ±×°Íµµ,°Ô´Ù°¡
  • both ~ and -
    ~ µµ - µµ (µÑ´Ù)
  • by and by
    ÀÌÀ¹°í
  • by-and-by
    ¹Ì·¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á